🇺🇸 FDA
Patent

US 12145974

Dual-target fusion proteins comprising FGF21 and GLP-1, connected through a Fc portion of an immunoglobulin

granted A61KA61K38/00A61P

Quick answer

US patent 12145974 (Dual-target fusion proteins comprising FGF21 and GLP-1, connected through a Fc portion of an immunoglobulin) held by SUNSHINE LAKE PHARMA CO., LTD. expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
SUNSHINE LAKE PHARMA CO., LTD.
Grant date
Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K38/00, A61P, A61P1/16, A61P3/04